| 90 | 0 | 849 |
| 下载次数 | 被引频次 | 阅读次数 |
中国临床肿瘤学会（Chinese Society of Clinical Oncology, CSCO）是中国肿瘤领域权威学术组织，致力于肿瘤诊断治疗的规范化，推动中国特色肿瘤研究与临床实践创新。CSCO恶性黑色素瘤诊疗指南是全球首个按皮肤、肢端、黏膜和葡萄膜等不同亚型制定诊疗方案的指南。目前该指南已更新至2025年版。美国国家综合癌症网络（National Comprehensive Cancer Network, NCCN）是由32家世界知名癌症中心组成的非营利性联盟组织，每年持续更新多种恶性肿瘤临床实践指南。NCCN指南不仅是美国肿瘤领域临床决策的金标准，更是全球应用范围最广泛的肿瘤临床实践指南之一。目前NCCN皮肤黑色素瘤临床实践指南已更新至2025年V2版。本文对上述CSCO和NCCN新版黑色素瘤指南的更新内容进行逐一解读。
Abstract：The Chinese Society of Clinical Oncology (CSCO) is an authoritative academic organization in the field of oncology in China, dedicated to standardizing cancer diagnosis and treatment, and promoting the innovation of oncology research and clinical practice with Chinese characteristics. CSCO melanoma guidelines are the first to formulate diagnosis and treatment plans based on different subtypes such as cutaneous, acral, mucosal, and uveal melanoma in the world. Currently, CSCO guidelines have been updated to the 2025 version. The National Comprehensive Cancer Network (NCCN) is a non-profit alliance consisting of 32 world-renowned cancer centers, which continuously updates clinical practice guidelines for various malignant tumors every year. NCCN guidelines are not only the gold standard for clinical decision-making in the field of oncology in the United States, but also one of the most widely used clinical practice guidelines for oncology globally. Currently, NCCN clinical practice guidelines in oncology for cutaneous melanoma have been updated to version 2.2025. This article will interpret the updated contents of the above-mentioned new versions of CSCO and NCCN melanoma guidelines.
[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] Han BF, Zheng RS, Zeng HM, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[3] Wu XC, Eide MJ, King J, et al. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States, 1999-2006[J]. J Am Acad Dermatol, 2011, 65(5): S26. e1-S26. e13.
[4] Wang Y, Zhao YJ, Ma SG. Racial differences in six major subtypes of melanoma: descriptive epidemiology[J]. BMC Cancer, 2016, 16(1): 691.
[5] Bai X, Kong Y, Chi ZH, et al. MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients: a retrospective study of 2, 793 cases[J]. Clin Cancer Res, 2017, 23(20): 6120-6127.
[6] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)黑色素瘤诊疗指南2025[M]. 北京: 人民卫生出版社, 2025.
[7] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)黑色素瘤诊疗指南2024[M]. 北京: 人民卫生出版社, 2024.
[8] Swetter SM, Johnson D, Abrams I, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Melanoma: Cutaneous. Version 2.2025[EB/OL]. (2025-1-28)[2025-6-6]. https://www.nccn.org/guidelines.
[9] Swetter SM, Johnson D, Abrams I, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Melanoma: Cutaneous. Version 2.2024[EB/OL]. (2024-4-3)[2025-6-6]. https://www.nccn.org/guidelines.
[10] Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage Ⅲ melanoma[J]. N Engl J Med, 2024, 391(18): 1696-1708.
[11] Patel SP, Othus M, Chen YB, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma[J]. N Engl J Med, 2023, 388(9): 813-823.
[12] Long GV, Carlino MS, McNeil C, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase Ⅲ KEYNOTE-006 study[J]. Ann Oncol, 2024, 35(12): 1191-1199.
[13] Arance A, Berciano-Guerrero MA, Guo J, et al. Randomized, double-blind, phase Ⅲ LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma[J]. Ann Oncol, 2025, 36(12): 1535-1546.
[14] Sheng XN, Huang G, Fang MY, et al. Toripalimab vs dacarbazine as first-line therapy for advanced melanoma of acral subtype: the phase 3 MELATORCH randomized clinical trial[J]. JAMA Oncol, 2026, Epub ahead of print.
[15] Ferrucci PF, Di Giacomo AM, Del Vecchio M, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma[J]. J Immunother Cancer, 2020, 8(2): e001806.
[16] Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2020, 395(10240): 1835-1844.
[17] Ascierto PA, Stroyakovskiy D, Gogas H, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study[J]. Lancet Oncol, 2023, 24(1): 33-44.
[18] Dummer R, Long GV, Robert C, et al. Randomized phase Ⅲ trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma[J]. J Clin Oncol, 2022, 40(13): 1428-1438.
[19] Wu JW, Ding QY, Zhang Q, et al. Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAFV600-mutant advanced melanoma: a multicenter cohort study[J]. MedComm, 2025, 6(3): e70102.
[20] Mao LL, Li CL, Dai J, et al. Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage Ⅱ/Ⅲ acral melanoma: The CAP 03-NEO trial[J]. J Clin Oncol, 2025, 43(16_suppl): 9512.
[21] Liu JY, Wang X, Li ZW, et al. Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ⅰb trial[J]. Signal Transduct Target Ther, 2024, 9(1): 318.
[22] Mao LL, Lian B, Li CL, et al. Camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma: the CAP 03 phase 2 nonrandomized clinical trial[J]. JAMA Oncol, 2023, 9(8): 1099-1107.
[23] Mao LL, Fang MY, Chen Y, et al. Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase Ⅱ study[J]. Clin Cancer Res, 2022, 28(21): 4642-4648.
[24] Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma[J]. N Engl J Med, 2021, 385(13): 1196-1206.
[25] Hassel JC, Piperno-Neumann S, Rutkowski P, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma[J]. N Engl J Med, 2023, 389(24): 2256-2266.
[26] Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type[J]. Mod Pathol, 2009, 22(11): 1446-1456.
[27] Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage ⅡB or ⅡC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial[J]. Lancet, 2022, 399(10336): 1718-1729.
[28] Luke JJ, Ascierto PA, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage ⅡB or ⅡC melanoma: final analysis of distant metastasis-free survival in the phase Ⅲ KEYNOTE-716 study[J]. J Clin Oncol, 2024, 42(14): 1619-1624.
[29] Kirkwood JM, Del Vecchio M, Weber J, et al. Adjuvant nivolumab in resected stage ⅡB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial[J]. Nat Med, 2023, 29(11): 2835-2843.
[30] Albiges L, Bourlon MT, Chacón M, et al. Subcutaneous versus intravenous nivolumab for renal cell carcinoma[J]. Ann Oncol, 2025, 36(1): 99-107.
[31] Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma[J]. N Engl J Med, 2019, 381(7): 626-636.
[32] Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage Ⅲ BRAF-mutated melanoma[J]. N Engl J Med, 2017, 377(19): 1813-1823.
[33] Long GV, Hauschild A, Santinami M, et al. Final results for adjuvant dabrafenib plus trametinib in stage Ⅲ melanoma[J]. N Engl J Med, 2024, 391(18): 1709-1720.
[34] Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma[J]. Nature, 2022, 611(7934): 155-160.
[35] Reijers ILM, Rawson RV, Colebatch AJ, et al. Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage Ⅲ melanoma[J]. JAMA Surg, 2022, 157(4): 335-342.
[36] Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage Ⅲ melanoma: the PRADO trial[J]. Nat Med, 2022, 28(6): 1178-1188.
[37] Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma[J]. J Clin Oncol, 2021, 39(24): 2656-2666.
[38] Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study[J]. J Immunother Cancer, 2022, 10(12): e005755.
基本信息:
DOI：10.13267/j.cnki.syzlzz.2026.001
引用信息:
[1]杜羽,毛丽丽.2025年黑色素瘤中国临床肿瘤学会和美国国家综合癌症网络指南更新解读[J],2026,41(1):1-6.DOI:10.13267/j.cnki.syzlzz.2026.001.
基金信息:
研究型病房卓越临床研究计划项目（BRWEP2024W032150200, BRWEP2024W032150202）